Huntsworth plc Share Price

Equities

HNT

GB00B0CRWK29

Advertising & Marketing

Delayed London S.E. 09:05:21 30/04/2020 pm IST 5-day change 1st Jan Change
107.5 GBX -.--% Intraday chart for Huntsworth plc -.--% +32.06%

Financials

Sales 2018 225M 281M 23.43B Sales 2019 265M 331M 27.58B Capitalization 301M 376M 31.33B
Net income 2018 21M 26.23M 2.19B Net income 2019 20M 24.98M 2.08B EV / Sales 2018 2 x
Net Debt 2018 77M 96.19M 8.02B Net Debt 2019 115M 144M 12.02B EV / Sales 2019 1.57 x
P/E ratio 2018
17.7 x
P/E ratio 2019
15.1 x
Employees -
Yield 2018
2.13%
Yield 2019
3.19%
Free-Float 0%
More Fundamentals * Assessed data
Dynamic Chart
Huntsworth Limited acquired The Cirkle Partnership Limited. CI
Huntsworth Limited announced that it has received funding from Clayton, Dubilier & Rice, LLC CI
Huntsworth plc completed the acquisition of Nucleus Global Limited. CI
Huntsworth plc entered into an agreement to acquire Nucleus Global Limited. CI
Nicky Dulieu Step Down as Non-Executive Director of Huntsworth plc CI
Huntsworth plc(LSE:HNT) dropped from FTSE All-Small Index CI
Huntsworth plc(LSE:HNT) dropped from FTSE All-Share Index CI
Clayton, Dubilier & Rice Fund X, L.P., Clayton, Dubilier & Rice Fund X-A, L.P., CD&R Advisor Fund X, L.P., funds managed by Clayton, Dubilier & Rice, LLC completed the acquisition of Huntsworth plc from Aberforth Partners LLP, Kabouter Management L.L.C., Kames Capital plc, Merian Global Investors (UK) Limited, Hargreave Hale Limited and others. CI
Huntsworth plc Proposes Final Dividend, Payable on September 18, 2020 CI
Huntsworth : U.S. buyout firm CD&R to buy UK's Huntsworth for £400 million in pharma bet RE
Huntsworth plc Propose Final Dividend for the Year Ended 31 December 2019, Payable on 6 July 2020 CI
Huntsworth plc Reports Earnings Results for the Full Year Ended December 31, 2019 CI
Clayton, Dubilier & Rice Fund X, L.P., Clayton, Dubilier & Rice Fund X-A, L.P., CD&R Advisor Fund X, L.P. funds managed by Clayton, Dubilier & Rice, LLC reached an agreement to acquire Huntsworth plc from Aberforth Partners LLP, Kabouter Management L.L.C., Kames Capital plc, Merian Global Investors (UK) Limited, Hargreave Hale Limited and others for approximately £400 million. CI
Huntsworth plc Provides Revenue Guidance for the Year Ending December 31, 2019 CI
A selection of British stocks to play the Brexit game Our Logo
More news
Managers TitleAgeSince
Director of Finance/CFO 58 01/16/01
Compliance Officer 57 01/08/01
Members of the board TitleAgeSince
Director of Finance/CFO 58 01/16/01
Director/Board Member 63 -
Director/Board Member - -
More insiders
Huntsworth Limited is a United Kingdom-based intermediate holding company. The Company is engaged in healthcare and communication activities. The Company, through its subsidiaries, is focused on health that provides marketing and medical communications services to healthcare clients, which are primarily large and mid-size pharmaceuticals and biotechnology companies. It also provides a range of communications and advisory services, including strategic communications, public affairs, investor relations and consumer marketing. The Company’s financial instruments comprise bank loans, bank overdrafts, loan notes, and cash and short-term deposits. The Company’s geographical areas include the United Kingdom, Europe, the United States and the rest of the world. The Company’s subsidiaries operate in approximately 28 in the United Kingdom and Europe.
More about the company